clinical trial · NCT00389740
A Comparison Study With Alendronate and Raloxifene in Postmenopausal Women With Osteoporosis (0217-189)
Organon and Co·phase3·completed·n = 400
Osteoporosis, PostmenopausalMK0217, /Duration of Treatment : 12 MonthsComparator : raloxifene hydrochloride /Duration of Treatment : 12 Months
brief summary
The purpose of this study is to compare how well alendronate and raloxifene increase the bone density in women who have osteoporosis and have experienced menopause.
started
Apr 2, 2001
primary completion
Jan 16, 2003
completion
Jan 16, 2003
last updated
Aug 14, 2024
official title
A Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter Study to Evaluate and Compare the Effects of Alendronate and Raloxifene on Bone Mineral Density in Postmenopausal Women With Osteoporosis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol